Target- |
Mechanism- |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.KR |
First Approval Date01 Dec 2010 |
Target- |
MechanismImmunomodulators |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date18 Nov 2005 |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
Inactive Indication- |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase Ⅲ Clinical Study to Evaluate Efficacy and Safety of AYP-101 for the Reduction of Submental Fat in Adults
To Evaluate Efficacy and Safety of AYP-101 S.C injection for the Reduction of Submental Fat in Adults
A Randomized, Double-blind, Placebo-controlled, Single Center and Single Dose Phase Ⅰ Study to Evaluate Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of AYP-101 S.C. Injection in Healthy Subjects
To Evaluate Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of AYP-101 S.C. injection in Healthy Subjects
A Randomized, Double-blind, Placebo-controlled, Single Center and Single Dose
A Single Center, Randomized, Placebo Controlled Phase Ⅱ Study to Determine the Dosing Interval and the Optimal Dose of AYP-101 S.C. Injection for the Reduction of Submental Fat
To determine the dosing interval, optimal dose, evaluate safety, and efficacy of AYP-101 S.C injection for the reduction of Submental Fat (SMF).
100 Clinical Results associated with Ami Pharm Co., Ltd.
0 Patents (Medical) associated with Ami Pharm Co., Ltd.
100 Deals associated with Ami Pharm Co., Ltd.
100 Translational Medicine associated with Ami Pharm Co., Ltd.